Cargando…
Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease
The aim of our study was to establish empirically to what extent reduced glucose uptake in the precuneus, posterior cingulate and/or temporo-parietal cortex (PCTP), which is thought to indicate brain amyloidosis in patients with dementia or MCI due to Alzheimer’s Disease (AD), permits to distinguish...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293827/ https://www.ncbi.nlm.nih.gov/pubmed/35347453 http://dx.doi.org/10.1007/s00415-022-11086-y |
_version_ | 1784749721096552448 |
---|---|
author | Isella, Valeria Crivellaro, Cinzia Formenti, Anna Musarra, Monica Pacella, Sara Morzenti, Sabrina Ferri, Francesca Mapelli, Cristina Gallivanone, Francesca Guerra, Luca Appollonio, Ildebrando Ferrarese, Carlo |
author_facet | Isella, Valeria Crivellaro, Cinzia Formenti, Anna Musarra, Monica Pacella, Sara Morzenti, Sabrina Ferri, Francesca Mapelli, Cristina Gallivanone, Francesca Guerra, Luca Appollonio, Ildebrando Ferrarese, Carlo |
author_sort | Isella, Valeria |
collection | PubMed |
description | The aim of our study was to establish empirically to what extent reduced glucose uptake in the precuneus, posterior cingulate and/or temporo-parietal cortex (PCTP), which is thought to indicate brain amyloidosis in patients with dementia or MCI due to Alzheimer’s Disease (AD), permits to distinguish amyloid-positive from amyloid-negative patients with non-classical AD phenotypes at the single-case level. We enrolled 127 neurodegenerative patients with cognitive impairment and a positive (n. 63) or negative (n. 64) amyloid marker (cerebrospinal fluid or amy-PET). Three rating methods of FDG-PET scan were applied: purely qualitative visual interpretation of uptake images (VIUI), and visual reading assisted by a semi-automated and semi-quantitative tool: INLAB, provided by the Italian National Research Council, or Cortex ID Suite, marketed by GE Healthcare. Fourteen scans (11.0%) patients remained unclassified by VIUI or INLAB procedures, therefore, validity values were computed on the remaining 113 cases. The three rating approaches showed good total accuracy (77–78%), good to optimal sensitivity (81–93%), but poorer specificity (62–75%). VIUI showed the highest sensitivity and the lowest specificity, and also the highest proportion of unclassified cases. Cases with asymmetric temporo-parietal hypometabolism and a progressive aphasia or corticobasal clinical profile, in particular, tended to be rated as AD-like, even if biomarkers indicated non-amyloid pathology. Our findings provide formal support to the value of PCTP hypometabolism for single-level diagnosis of amyloid pathophysiology in atypical AD, but also highlight the risk of qualitative assessment to misclassify patients with non-AD PPA or CBS underpinned by asymmetric temporo-parietal hypometabolism. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-022-11086-y. |
format | Online Article Text |
id | pubmed-9293827 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-92938272022-07-20 Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease Isella, Valeria Crivellaro, Cinzia Formenti, Anna Musarra, Monica Pacella, Sara Morzenti, Sabrina Ferri, Francesca Mapelli, Cristina Gallivanone, Francesca Guerra, Luca Appollonio, Ildebrando Ferrarese, Carlo J Neurol Original Communication The aim of our study was to establish empirically to what extent reduced glucose uptake in the precuneus, posterior cingulate and/or temporo-parietal cortex (PCTP), which is thought to indicate brain amyloidosis in patients with dementia or MCI due to Alzheimer’s Disease (AD), permits to distinguish amyloid-positive from amyloid-negative patients with non-classical AD phenotypes at the single-case level. We enrolled 127 neurodegenerative patients with cognitive impairment and a positive (n. 63) or negative (n. 64) amyloid marker (cerebrospinal fluid or amy-PET). Three rating methods of FDG-PET scan were applied: purely qualitative visual interpretation of uptake images (VIUI), and visual reading assisted by a semi-automated and semi-quantitative tool: INLAB, provided by the Italian National Research Council, or Cortex ID Suite, marketed by GE Healthcare. Fourteen scans (11.0%) patients remained unclassified by VIUI or INLAB procedures, therefore, validity values were computed on the remaining 113 cases. The three rating approaches showed good total accuracy (77–78%), good to optimal sensitivity (81–93%), but poorer specificity (62–75%). VIUI showed the highest sensitivity and the lowest specificity, and also the highest proportion of unclassified cases. Cases with asymmetric temporo-parietal hypometabolism and a progressive aphasia or corticobasal clinical profile, in particular, tended to be rated as AD-like, even if biomarkers indicated non-amyloid pathology. Our findings provide formal support to the value of PCTP hypometabolism for single-level diagnosis of amyloid pathophysiology in atypical AD, but also highlight the risk of qualitative assessment to misclassify patients with non-AD PPA or CBS underpinned by asymmetric temporo-parietal hypometabolism. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-022-11086-y. Springer Berlin Heidelberg 2022-03-26 2022 /pmc/articles/PMC9293827/ /pubmed/35347453 http://dx.doi.org/10.1007/s00415-022-11086-y Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Communication Isella, Valeria Crivellaro, Cinzia Formenti, Anna Musarra, Monica Pacella, Sara Morzenti, Sabrina Ferri, Francesca Mapelli, Cristina Gallivanone, Francesca Guerra, Luca Appollonio, Ildebrando Ferrarese, Carlo Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease |
title | Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease |
title_full | Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease |
title_fullStr | Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease |
title_full_unstemmed | Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease |
title_short | Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease |
title_sort | validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of alzheimer’s disease |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293827/ https://www.ncbi.nlm.nih.gov/pubmed/35347453 http://dx.doi.org/10.1007/s00415-022-11086-y |
work_keys_str_mv | AT isellavaleria validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease AT crivellarocinzia validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease AT formentianna validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease AT musarramonica validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease AT pacellasara validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease AT morzentisabrina validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease AT ferrifrancesca validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease AT mapellicristina validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease AT gallivanonefrancesca validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease AT guerraluca validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease AT appollonioildebrando validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease AT ferraresecarlo validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease |